Vertex Pharmaceuticals Purchases Alpine Immune Sciences $4.9 Billion
Vertex Pharmaceuticals announced that it has agreed to acquire Seattle-based Alpine Immune Sciences for $4.9 billion. Alpine Immune Sciences is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. According to its most recent annual report, the company’s revenue for FY 2023 was approximately $58.9 million, and EBITDA was -$43.3 million. Vertex Pharmaceuticals is an American biopharmaceutical company based in... Read More »
Highbridge Capital Management Acquires Gamida Cell for $70 Million
Highbridge Capital Management, based in New York City, announced on March 27 that it entered into an agreement to acquire Gamida Cell, an Israeli biotechnology company. The agreement will see Highbridge Capital Management convert $75 million of existing unsecured convertible senior notes into equity in Gamida as well as supply $30 million of new capital to Gamida. Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. Its proprietary nicotinamide technology expands the number of cells while maintaining their intrinsic properties to create potentially curative cell therapy products and candidates for patients with cancer. Gamida entered 2024... Read More »
Novo Nordisk Inks $1 Billion Buyout of Cardior Pharmaceuticals
Novo Nordisk announced that it has agreed to acquire Cardior Pharmaceuticals for up to €1.025 billion (approximately $1.1 billion USD), including an upfront payment and additional payments if certain development and commercial milestones are achieved. The acquisition is an important step forward in Novo Nordisk’s strategy to establish a presence in the cardiovascular disease treatment space. Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse cardiovascular diseases. Cardior’s therapeutic approach uses distinctive non-coding RNAs as a platform for addressing... Read More »AbbVie Acquires Landos Biopharma for $137.5 Million
On March 25, Chicago-based AbbVie Inc. announced that it entered into an agreement to acquire Landos Biopharma for $137.5 million. AbbVie will acquire Landos at a price of $20.42 per share in cash upon closing, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone. Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class oral NLRX1... Read More »
AstraZeneca Acquires Fusion Pharmaceuticals for $2 Billion
AstraZeneca announced on March 19 that it entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., based in Hamilton, Canada. Fusion will become a wholly owned subsidiary of AstraZeneca, with operations continuing in Canada and the United States. The upfront cash portion of the consideration represents a transaction value of approximately $2 billion. Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of approximately $2.4 billion. Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RC). Fusion’s clinical-stage development portfolio includes its lead... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
